Please assess the completion status of the following clinical trial:

Trial Title: Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age 21-40 years~* Premenopausal~Exclusion Criteria:~Serum potassium ,\< 3.6 meq/l~* Serum magnesium \< 1.8 mg/dl~* Serum hemoglobin \< 9.0 mg/dl~* Serum hematocrit \< 26%~* Hypertension~* Coronary artery disease~* Heart failure~* Liver disease~* Kidney disease~* Serum creatinine \> 1.5 mg/dl~* Taking hormone contraceptives~* Baseline Bazett's correct QTc interval \> 450 ms~* Family history of long-QT syndrome, arrhythmias, sudden cardiac death~* Concomitant use of any QT prolonging drug~* Pregnancy~* weight \< 45 kg~* Unwillingness to use non-hormonal forms of birth control during the study period

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Progesterone (Type: EXPERIMENTAL): Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive oral placebo, two capsules once daily every evening for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).